Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    11418482 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
Condition: Multiple Myeloma
Intervention: Procedure: Maintenance with lower doses of lenalidomide and dexamethasone
2 Active, not recruiting Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up

Indicates status has not been verified in more than two years